<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322137</url>
  </required_header>
  <id_info>
    <org_study_id>SNA-120-201</org_study_id>
    <nct_id>NCT03322137</nct_id>
  </id_info>
  <brief_title>Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib) Ointment in Subjects With Pruritus Associated With Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sienna Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sienna Labs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To characterize the efficacy, safety and tolerability of SNA-120 at 2 doses versus placebo
      when administered topically for the treatment of pruritus associated with psoriasis vulgaris
      (PV) and PV itself.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Actual">October 22, 2018</completion_date>
  <primary_completion_date type="Actual">September 10, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Itch Numeric Rating Scale scores (I-NRS)</measure>
    <time_frame>week 1</time_frame>
    <description>The I-NRS is a 11 point scale, where &quot;0&quot; represents no itch and &quot;10&quot; represents worst possible itching</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Itch Numeric Rating Scale scores (I-NRS)</measure>
    <time_frame>week 2</time_frame>
    <description>The I-NRS is a 11 point scale, where &quot;0&quot; represents no itch and &quot;10&quot; represents worst possible itching</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Itch Numeric Rating Scale scores (I-NRS)</measure>
    <time_frame>week 4</time_frame>
    <description>The I-NRS is a 11 point scale, where &quot;0&quot; represents no itch and &quot;10&quot; represents worst possible itching</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Itch Numeric Rating Scale scores (I-NRS)</measure>
    <time_frame>week 6</time_frame>
    <description>The I-NRS is a 11 point scale, where &quot;0&quot; represents no itch and &quot;10&quot; represents worst possible itching</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Itch Numeric Rating Scale scores (I-NRS)</measure>
    <time_frame>week 8</time_frame>
    <description>The I-NRS is a 11 point scale, where &quot;0&quot; represents no itch and &quot;10&quot; represents worst possible itching</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects (≥ 1 grade change) on IGA scale</measure>
    <time_frame>week 12</time_frame>
    <description>Investigator Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects (≥ 2 grade change) on IGA scale</measure>
    <time_frame>week 12</time_frame>
    <description>Investigator Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects categorized as a &quot;0&quot; or &quot;1&quot; on IGA scale and minimum improvement of 2 categories</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Investigator Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PASI-50</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Percentage of subjects with 50% reductions in Psoriasis Area and Severity Index</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety measured by incidence and severity of adverse events</measure>
    <time_frame>up to 12 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by change in clinical laboratory results from baseline</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>urinalysis lab assessments</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by change in clinical laboratory results from baseline</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>biochemistry lab assessments</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by change in clinical laboratory results from baseline</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>hematology lab assessments</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by change in blood pressure from baseline</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>systolic/diastolic blood pressure (BP in mmHg)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by change in pulse from baseline</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Pulse (beats per minute [bpm])</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by number of abnormal physical examination changes</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Any abnormal physical examination changes from baseline and week 12</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by PR/PQ intervals measured by 12-lead ECG</measure>
    <time_frame>week 2</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by PR/PQ intervals measured by 12-lead ECG</measure>
    <time_frame>week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by PR/PQ intervals measured by 12-lead ECG</measure>
    <time_frame>week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by QRS duration measured by 12-lead ECG</measure>
    <time_frame>week 2</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by QRS duration measured by 12-lead ECG</measure>
    <time_frame>week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by QRS duration measured by 12-lead ECG</measure>
    <time_frame>week 12</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by QT interval measure by 12-lead ECG</measure>
    <time_frame>week 2</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by QT interval measure by 12-lead ECG</measure>
    <time_frame>week 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Safety measured by QT interval measure by 12-lead ECG</measure>
    <time_frame>week 12</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>Pruritus</condition>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>SNA-120 (0.05% )</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegcantratinib Ointment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SNA-120 (0.5%)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegcantratinib Ointment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SNA-120</intervention_name>
    <description>Pegcantratinib ointment</description>
    <arm_group_label>SNA-120 (0.05% )</arm_group_label>
    <arm_group_label>SNA-120 (0.5%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Placebo ointment to mimic Pegcantratinib ointment</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent/assent and Health Insurance Portability and Accountability Act
             (HIPAA) authorization

          -  Stable PV for at least 6 months prior to screening

          -  Chronic pruritus of the PV plaques to be present for at least 6 weeks prior to
             screening

          -  Mild to moderate PV at screening and baseline

          -  Has a target plaque at baseline on the trunk and/or limbs

          -  Subject's plaques are amenable to treatment with a topical ointment medication

          -  Willing and able to comply with the study instructions and attend all scheduled study
             visits.

          -  Willing to avoid prolonged exposure of the designated treatment plaques to ultraviolet
             radiation

          -  Females of childbearing potential must have a negative pregnancy test at baseline
             before randomization and must agree to use highly effective contraception during the
             study

          -  Men who are sexually active and can father children must agree to use highly effective
             forms of contraception during the study

        Exclusion Criteria:

          -  Underlying conditions other than psoriasis that, in the opinion of the investigator,
             currently cause or influence pruritus of the overall skin

          -  Positive hepatitis serology

          -  Thyroid abnormalities that may impact itching

          -  Subjects with spontaneously improving or rapidly deteriorating PV and/or pruritus

          -  Current diagnosis of guttate, erythrodermic, exfoliative, or pustular psoriasis

          -  Active psoriasis or itch affecting the palmar/plantar regions

          -  Subjects with a clinical diagnosis of bacterial infection of the skin

          -  Any major medical illness or symptoms of a clinically significant illness that may
             influence the study outcome

          -  Any acute chronic medical or psychiatric condition or laboratory abnormality that
             would make them unsuitable for participation in this study

          -  Known hypersensitivity to the study treatment excipients and /or polyethylene glycol,
             that contraindicates participation

          -  Currently enrolled in an investigational drug or device study or has used an
             investigational drug or an investigational device treatment within 30 days of
             randomization/baseline (Note: Subjects who are enrolled in a long-term follow-up study
             and are not actively receiving an investigational drug or investigational device
             treatment may be eligible for participation in this study)

          -  Female who is pregnant or lactating, or is planning to become pregnant during the
             study

          -  Subjects participating in any previous SNA-120 (and/or CT327) clinical studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 025</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 022</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 028</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 009</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 008</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 020</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 015</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 005</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 030</name>
      <address>
        <city>Shelton</city>
        <state>Connecticut</state>
        <zip>06484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 026</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 019</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 017</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 024</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 027</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 029</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 010</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 011</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 023</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 038</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 032</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 039</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 002</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 001</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 004</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 013</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 037</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 016</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 006</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 041</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 003</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 031</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 035</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 012</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 021</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 018</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 034</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 007</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sienna 014</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <disposition_first_submitted>February 4, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>February 4, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 8, 2019</disposition_first_posted>
  <last_update_submitted>February 4, 2019</last_update_submitted>
  <last_update_submitted_qc>February 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

